Metastatic melanoma imaging with an 111In-labeled lactam bridge-cyclized α-melanocyte-stimulating hormone peptide

Nuclear Medicine and Biology

Volumn 36, Issue 3, 2009, Pages 267-276

  Guo, Haixun ^a   Shenoy, Nalini ^a   Gershman, Benjamin M ^a   Yang, Jianquan ^a   Sklar, Larry A ^a,b,c   Miao, Yubin ^a,b,c  

^a UNIVERSITY OF NEW MEXICO   (United States)

^b UNIVERSITY OF NEW MEXICO   (United States)

^c UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

Metastatic melanoma imaging; Radiolabeled lactam bridge cyclized peptide; Melanocyte stimulating hormone

Indexed keywords

ALPHA MELANOCYTE STIMULATING HORMONE PEPTIDE IN 111; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CONTROL GROUP; CONTROLLED STUDY; LUNG METASTASIS; MELANOMA; NONHUMAN; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STATISTICAL SIGNIFICANCE;

EID: 62549146618     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2009.01.003     Document Type: Article

References (37)

1. Jemal A., Siegel R., and Ward E. Cancer statistics, 2008. CA Cancer J Clin 58 (2008) 71-96
2. Balch C.M., Soong S.J., and Gershenwald J.E. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 19 (2001) 3622-3634
3. Gambhir S.S. Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer 2 (2002) 683-693
4. Sharma V., Luker G.D., and Piwnica-Worms D. Molecular imaging of gene expression and protein function in vivo with PET and SPECT. J Magn Reson Imaging 16 (2002) 336-351
5. 99mTc-MIBI scintigraphy. J Nucl Med 44 (2003) 1561-1565
6. 18F-FDG in oncology. J Nucl Med Technol 30 (2002) 3-9
7. 15O-water using compartment and non-compartment analysis. J Nucl Med 42 (2001) 248-256
8. Tatro J.B., and Reichlin S. Specific receptors for alpha-melanocyte-stimulating hormone are widely distributed in tissues of rodents. Endocrinology 121 (1987) 1900-1907
9. Siegrist W., Solca F., and Stutz S. Characterization of receptors for alpha-melanocyte-stimulating hormone on human melanoma cells. Cancer Res 49 (1989) 6352-6358
10. 99mtechnetium-labeled cyclic α-melanocyte-stimulating hormone peptide analogues. Cancer Res 60 (2000) 5649-5658
11. 188Re-labeled alpha-melanocyte stimulating hormone peptide analogs for melanoma therapy. Int J Cancer 101 (2002) 480-487
12. Miao Y., Whitener D., Feng W., Owen N.K., Chen J., and Quinn T.P. Evaluation of the human melanoma targeting properties of radiolabeled alpha-melanocyte stimulating hormone peptide analogues. Bioconjug Chem 14 (2003) 1177-1184
13. 188Re labeled α-melanocyte stimulating hormone peptide analogue in murine and human melanoma-bearing mouse models. J Nucl Med 46 (2005) 121-129
14. Miao Y., Hylarides M., and Fisher D.R. Melanoma therapy via peptide-targeted α-radiation. Clin Cancer Res 11 (2005) 5616-5621
15. Froidevaux S., Calame-Christe M., Tanner H., Sumanovski L., and Eberle A.N. A novel DOTA-α-melanocyte-stimulating hormone analog for metastatic melanoma diagnosis. J Nucl Med 43 (2002) 1699-1706
16. Froidevaux S., Calame-Christe M., and Schuhmacher J. A gallium-labeled DOTA-α-melanocyte-stimulating hormone analog for PET imaging of melanoma metastases. J Nucl Med 45 (2004) 116-123
17. Froidevaux S., Calame-Christe M., Tanner H., and Eberle A.N. Melanoma targeting with DOTA-alpha-melanocyte-stimulating hormone analogs: structural parameters affecting tumor uptake and kidney uptake. J Nucl Med 46 (2005) 887-895
18. 111In-labeled lactam bridge-cyclized alpha-melanocyte stimulating hormone peptide analogues for melanoma imaging. Bioconjug Chem 19 (2008) 539-547
19. 10]-α-melanocyte-stimulating hormone: a cyclic α-melanotropin exhibiting superagonist biological activity. Proc Natl Acad Sci U S A 79 (1982) 1751-1755
20. Al-Obeidi F., Hadley M.E., Pettitt B.M., and Hadley M.E. Design of a new class of superpotent cyclic α-melanotropins based on quenched dynamic simulations. J Am Chem Soc 111 (1989) 3413-3416
21. Al-Obeidi F., de L Castrucci A.M., Hadley M.E., and Hruby V.J. Potent and prolonged-acting cyclic lactam analogs of a-melanotropin: design based on molecular dynamics. J Med Chem 32 (1989) 2555-2561
22. Fung S., and Hruby V.J. Design of cyclic and other templates for potent and selective peptide α-MSH analogues. Curr Opin Chem Biol 9 (2005) 352-358
23. Fidler I.J. Biological behavior of malignant melanoma cells correlated to their survival in vivo. Cancer Res 35 (1975) 218-224
24. 2: a potential small-molecule single-photon emission computed tomography probe for imaging metastatic melanoma. Cancer Res 65 (2005) 4979-4986
25. Winkelmann C.T., Figueroa S.D., Rold T.L., and Volkert W.A. Microimaging characterization of a B16-F10 melanoma metastasis mouse model. Mol Imaging 5 (2006) 105-114
26. Fidler I.J., and Kripke M.L. Metastasis results from preexisting variant cells within a malignant tumor. Science 197 (1977) 893-895
27. Vantyghem S.A., Postenka C.O., and Chambers A.F. Estrous cycle influences organ-specific metastasis of B16F10 melanoma cells. Cancer Res 63 (2003) 4763-4765
28. Yang M., Jiang P., and An Z. Genetically fluorescent melanoma bone and organ metastasis models. Clin Cancer Res 5 (1999) 3549-3559
29. Yang M., Baranov E., and Jiang P. Whole-body optical imaging of green fluorescent protein-expressing tumors and metastases. Proc Natl Acad Sci U S A 97 (2000) 1206-1211
30. Hoffman R.M. Green fluorescent protein imaging of tumour growth, metastasis, and angiogenesis in mouse models. Lancet Oncol 3 (2002) 546-556
31. Arguello F., Baggs R.B., and Frantz C.N. A murine model of experimental metastasis to bone and bone marrow. Cancer Res 48 (1988) 6876-6881
32. Volkert W.A., and Hoffman T.J. Therapeutic radiopharmaceuticals. Chem Rev 99 (1999) 2269-2292
33. 111In-labeled α-melanocyte-stimulating hormone peptides as imaging probes for primary and pulmonary metastatic melanoma detection. J Nucl Med 48 (2007) 73-80
34. Otte A., Jermann E., Behe M., et al. A powerful new tool for receptor-mediated radionuclide therapy. Eur J Nucl Med 24 (1997) 792-795
35. Otte A., Mueller-Brand J., Dellas S., Nitzsche E.U., Herrmann R., and Maecke H.R. Yttrium-90-labelled somatostatin-analogue for cancer treatment. Lancet 351 (1998) 417-418
36. Zamora P.O., Bender H., Gulhke S., et al. Pre-clinical experience with Re-188-RC-160, a radiolabeled somatostatin analog for use in peptide-targeted radiotherapy. Anticancer Res 17 (1997) 1803-1808
37. 3]octreotate for somatostatin receptor-targeted radionuclide therapy. Int J Cancer 92 (2001) 628-633